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Abstract
Study Design: Systematic review.
Objectives: To review the current literature on the treatment efficacy, clinical utility, and cost-effectiveness of multidisciplinary
biopsychosocial rehabilitation (MBR) for patients suffering from persistent (nonspecific) lower back pain (LBP) in relation to pain
intensity, disability, health-related quality of life, and work ability/sick leave.
Methods: We carried out a systematic search of Web of Science, Cochrane Library, PubMed Central, EMBASE, and PsycINFO
for English- and German-language literature published between January 2010 and July 2017. Study selection consisted of exclusion
and inclusion phases. After screening for duplication, studies were excluded on the basis of criteria covering study design, number
of participants, language of publication, and provision of information about the intervention. All the remaining articles dealing with
the efficacy, utility, or cost-effectiveness of intensive (more than 25 hours per week) MBR encompassing at least 3 health domains
and cognitive behavioral therapy–based psychological education were included.
Results: The search retrieved 1199 publications of which 1116 were duplicates or met the exclusion criteria. Seventy of the
remaining 83 articles did not meet the inclusion criteria; thus 13 studies were reviewed. All studies reporting changes in pain
intensity or disability over 12 months after MBR reported moderate effect sizes and/or p-values for both outcomes. The effects on
health-related quality of life were mixed, but MBR substantially reduced costs. Overall MBR produced an enduring improvement
in work ability despite controversy and variable results.
Conclusions: MBR is an effective treatment for nonspecific LBP, but there is room for improvement in cost-effectiveness and
impact on sick leave, where the evidence was less compelling.
Keywords
persistent low back pain, multidisciplinary rehabilitation, cognitive behavioral therapy, efficacy, treatment utility, cost-effectiveness,
systematic review
Introduction
Nonspecific lower back pain (NSLBP), and in particular per-
sistent (ie, of at least 12 weeks’ duration1), NSLBP without
structural origin, results in a considerable global socioeco-
nomic burden2 and disability.3 Although NSLBP is very com-
mon, with lifetime and point prevalences of up to 84% and
40%, respectively,4,5 the literature does not differentiate con-
sistently between LBP and NSLBP, or persistent LBP and
persistent NSLBP, forcing us to consider both terms in this
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article. LBP6 reduces quality of life and work performance6 and
the proportion of people affected is projected to increase as
society ages,7 thus the condition is a real cause of concern and
requires new and innovative management strategies.8 The per-
sonal and societal costs of managing LBP are high, below only
cardiovascular disease and diabetes in the United States9 and
although treatment uptake and the range of treatments available
have increased dramatically,9,10 treatment results are less con-
vincing, leading to enormous economic and health care costs
every year.3,11 All parties with an interest in the management of
LBP or NSLBP—patients, health care providers, and health
care systems—need better knowledge about the efficacy,
clinical utility, and cost-effectiveness of current treatments.
Efficacy, Clinical Utility, and Cost Effectiveness of
Treatments for Persistent LBP or Persistent NSLBP
Several factors determine the quality of an intervention.
A medical treatment is considered effective if there is evidence
that it eliminates or reduces a given health problem.12 If a
treatment is feasible, useful and can be applied in a range of
settings it is considered to have clinical utility.12 A treatment is
cost-effective if it provides the best treatment alternative in
economic terms.13 In German-speaking countries, health
insurers will cover the costs of a medical treatment if it has
proven treatment efficacy, clinical utility, and cost-effective-
ness14; this is not true of all first-world countries. Health care
insurers in the United States, for example, are permitted to
focus on cost-containment and profitability and, therefore, will
not reimburse patients for services or drugs.15
In recent years, only a few articles have reviewed the effi-
cacy, clinical utility and cost-effectiveness of treatments for
persistent LBP or persistent NSLBP.16-22 This article reviews
recent evidence, covering the period up to July 2017.
Multidimensionality of Persistent LBP or Persistent NSLBP
Persistent LBP or persistent NSLBP represents a complex inter-
action of physical, psychological, social and environmental com-
ponents, including both genetic and cultural factors.23,24
Potential treatments should take this into account and encompass
a representative range of medical disciplines and disciplines
allied to medicine, combined so as to offer maximum benefit
to patients. In their Cochrane systematic review, Kamper et al19
confirmed the efficacy of multidisciplinary biopsychosocial
rehabilitation (MBR) but were not completely able to proof its
cost-effectiveness.19
Definition of Inter- or Multidisciplinary Treatment
MBR is based on Engel’s 1977 biopsychosocial (BPS) model,
according to which biological, psychological, and social fac-
tors influence the course of a disease.25 To date, however,
there is no consensus on terminology for describing such
treatments. In their latest Cochrane review Kamper et al19
describe MBR as an integrated intervention that involves at
least 2 of the following: physical, psychological, social, and
work-related factors. They also note that the therapeutic team
should comprise a minimum of 2 different health care profes-
sionals, for example, a medical doctor (physician or psychia-
trist) and a clinical psychologist or physical therapist, who
communicate extensively about the management of patients.
Additional team members, such as an occupational therapist,
exercise therapist, or social worker, can be integrated when
necessary.19 Gatchel et al24 differentiate between multidisci-
plinary interventions, involving several health care profes-
sions and interdisciplinary interventions in which the team
has a common understanding of rehabilitation and is in con-
stant communication, and the patient is actively involved in
treatment planning. Although there is no universally accepted
definition of MBR, the primary aim of MBR appears to be
reduction of pain-maintaining factors.19,24,26,27 For the pur-
poses of this review, we have used Kamper et al’s definition
and required MBR to involve weekly meetings of the thera-
peutic team at which individuals’ treatment is discussed.24
Furthermore, we followed the recommendation of Guzman
et al17 to employ MBRs with a high treatment intensity of
at least 25 hours per week. MBR also typically involves cog-
nitive behavioral therapy (CBT) to help the individual iden-
tify and replace maladaptive thoughts, emotions and
behaviors.24 Thus CBT is often integrated into MBR, gener-
ally in the form of group therapy as this is considered to
represent the most cost-effective use of resources.1,28 Using
this definition, we reviewed the literature between 2010 and
2017 in order to identify studies reporting on CBT-based
MBR interventions of any design, provided they comprised
at least 25 hours of treatment per week and involved at least 3
health professions. We examined the efficacy, clinical utility,
and cost-effectiveness of these MBR interventions as treat-
ments for persistent LBP or persistent NSLBP.
Material and Methods
Data Sources
An electronic and manual search of the English- and German-
language literature was performed. The electronic search cov-
ered November 2016 to July 2017 in the databases Web of
Science, Cochrane Library, PubMed Central, EMBASE and
PsycINFO (January 2010 to July 2017). The search string
entered was (efficacy OR effectiveness OR efficiency OR ther-
apeutic effects OR utility OR cost effectiveness) AND (multi-
disciplinary treatment OR interdisciplinary treatment OR
multidisciplinary rehabilitation OR functional restoration OR
cognitive-behavioral pain management program OR func-
tional centered rehabilitation) AND (low back pain OR
non-specific low back pain OR persistent low back pain OR
persistent non-specific low back pain). This search was supple-
mented with a manual check of references in articles included
in recent reviews and work by authors known to publish in this
area. The cutoff date for the retrieval of articles from libraries
was July 31, 2017. The selected studies were compiled into an
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electronic list that formed the basis of the second step in the
selection process, which is described below.
Literature Screening
Studies were selected through a systematic 2-step screening
process. In spring 2017, the first rater (SS, junior psychologist,
conversational bilingual German and English expertise)
screened all titles, authors, and abstracts, and removed dupli-
cates. Next the articles were reviewed by 2 independent raters
(SS; CRS, senior psychologist, advanced bilingual German and
English expertise) in order to exclude publications that were
abstract only, case reports, letters, comments, or reviews; stud-
ies based on fewer than 15 patients (due to reduced general-
izability of results); publications in languages other than
English or German; publications where there was insufficient
information to determine whether the intervention met our cri-
teria for MBR. The full texts of all remaining articles were
obtained in digital format. In the third phase, both raters (SS
and CRS) selected all articles that examined the efficacy, clin-
ical utility, or cost-effectiveness of MBR, where the MBR
consisted of more than 25 hours of treatment per week deliv-
ered by at least 3 different health professions as well as CBT-
based psychological education.
Study Selection for Data Extraction
At least one out of several outcomes should be reported in the
selected studies29: pain intensity (eg, visual analogue scale,
VAS30; Numeric rating Scale, NRS31), disability (eg, Oswestry
Disability Index, ODI32; Roland Morris Disability Question-
naire, RMDQ33), health-related quality of life (HRQoL; eg,
Short Form–36, SF-3635), and work ability/sick leave (eg,
length of absence from work). We also extracted the following
study characteristics and demographic variables: study loca-
tion, and outcomes; treatment duration; specific information
about the treatment; nature of the control and treatment groups;
the disciplined incorporated into treatment; measurement
times; sample size; gender distribution and mean age of
sample.29
To ensure a transparent and complete reporting of the
review, this study followed the Preferred Reporting Items for
Systematic Reviews and Meta-Analysis (PRISMA) state-
ment.35,36 Furthermore, the Grading of Recommendations
Assessment, Development and Evaluation (GRADE) approach
was chosen to rate the quality of evidence.37 GRADE was
developed by a widely representative group of international
guideline developers with the aim to clearly separate between
the quality of evidence and the strengths of recommendations.
Explicit, simple, transparent, and comprehensive criteria for
down- or upgrading quality-of-evidence ratings are described
for the study design, study limitations, inconsistency of results,
indirectness of evidence, imprecision, and publication bias of a
publication—finally offering 4 quality-of-evidence classifica-
tions (high, moderate, low, and very low).37
Statistics
Where available, effect sizes (ESs) and P values are reported.
An ES is a quantitative measure of the strength of an outcome.
It represents the difference between pre- and postmeasurements
divided by a pooled standard deviation. ESs can be categorized
as follows: ES 0.20 ¼ small effect, ES 0.50 ¼ moderate
effect and ES 0.80 ¼ large effect.38 P value has been defined
as “[ . . . ] the probability under a specified statistical model that
a statistical summary of the data (e.g., the sample mean differ-
ence between two compared groups) would be equal to or more
extreme than its observed value.”39(p131) Although P values
indicate the level of compatibility with a specified statistical
model (null hypothesis, H0), they must be understood as a
statement about data in relation to a specified hypothesis. A
P value is a measure of statistical significance, but it does not
indicate the size of an effect or the clinical importance of a
result.39(p132) In this study, the smaller the P value, the greater
the statistical incompatibility of the data with H0 (pre- and
posttreatment measurements are similar).
Results
Data Retrieval
The initial literature review identified 1199 publications of
which 1116 were rejected as duplicates (n ¼ 784) or because
they met exclusion criteria (n¼ 332). Seventy of the remaining
83 articles did not meet the inclusion criteria, leaving a sample
of 13 primary studies for review (Figure 1).40-54 Twelve studies
examined the efficacy of MBR, 3 investigated cost-
effectiveness, and 1 examined clinical utility. Three of the 13
studies examined 2 or more of these variables.
Study Characteristics
All 13 extracted studies were longitudinal studies conducted in
Europe; they comprised 4 randomized controlled trials, 6 pro-
spective studies, 2 cost analyses, and 1 retrospective study
(Table 1). The number of hours of therapy per week ranged
from 25 to 50 and the total for the intervention from 97.5 to
150. According to the GRADE37 criteria, 1 study provided
high-quality evidence and 1 moderate-quality evidence, but the
rest had limitations (Table 2).
Characteristics of Participants
There were 2002 patients enrolled in MBRs and 947 subjects in
various control groups. Approximately 49% of all enrolled
patients were female and the overall average age of patients
was 43 years. All studies but one included participants with
persistent NSLBP lasting at least 3 months. The exception was
Rantonen et al,50 who included participants with acute or recur-
rent LBP employed by a forestry company and unsurprisingly,
the histories of this patient group are clearly different from the
other, more typical histories of participants on sick leave due to
persistent LBP or persistent NSLBP (Table 3).
874 Global Spine Journal 8(8)
Outcome Measures
There were some differences between the outcome variables
used in the studies included in this review; however, 11 of the
13 studies reported data on work ability and sick leave. Sev-
eral studies investigated disability and HRQoL using various
tools (Table 1) in addition to pain intensity. The following
sections provide an overview of the various outcome
measures.
Pain Intensity. Eight studies examined changes in pain inten-
sity over the 12 months following MBR; most used similar
tools (VAS30 or NRS31). Comparisons of pre- and posttreat-
ment scores revealed moderate to large ESs or P values in
pain reduction (ES 0.6 to 0.74; P ¼ .003 to P < .001). In
studies that assessed patients over a longer period, the
reduction in pain intensity persisted for at least 24 months
(P < .01; Table 4).
Disability. The 8 studies reporting disability used 7 different
instruments (Dallas Pain Questionnaire, DPQ55; Funktions-
fragebogen Hannover, FFbH-R56; ODI32; SF-3634; Spinal
Function Sort, SFS57; Pain Disability Index–German Ver-
sion, PDI-G58; 18-item version of the Roland Morris Dis-
ability Questionnaire, RMDQ-1859), rendering direct
comparisons difficult. Nevertheless, all comparisons
between pre- and posttreatment scores revealed moderate
to large ESs or P values for reduction in functional disabil-
ity (ES 0.4 to 0.8; P < .01 to P < .001; Table 4). Reduction
in pain-related disability persisted for 24 months in the
studies that examined a longer time frame (P < .05 to P <
.001). Rantonen et al,50 who included non-sick-listed
employees, reported neither short- nor long-term changes
in disability (Table 4).
Health-Related Quality of Life. Four different instruments were
used to assess HRQoL (DPQ55; Life Satisfaction Questionnaire
11; LiSat-1160; SF-3634; generic 15-dimensional self-
administered 15D instrument61), which probably contributed
to the conflicting results. Three studies found no long-term
increase in the HRQoL after MBR: Caby et al43 found a
short-term reduction in one HRQoL variable43 and neither Ran-
tonen et al50 nor Merrick et al48 detected any change in HRQoL
(Table 4). The other 4 studies reported moderate to large
increases in HRQoL that persisted for at least 12 months (ES
0.5 to 0.8; P < .05 to P < .001).
Cost-Effectiveness. Three of the 12 studies examined economic
parameters of MBR and all demonstrated that indirect costs























on Additional records identified 
through other sources 
(n = 36)







assessed for eligibility 
(n = 83)
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Figure 1. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) 2009 flow diagram.



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































substantially exceed direct costs and that MBR produced a
substantial reduction in direct and indirect costs (Table 5).
Henchoz et al46 found that direct and indirect monthly costs
were, respectively, 94% and 84% lower 12 months after treat-
ment (P ¼ .004) while quality-adjusted life years (QALYs)
remained stable over the 12 months following treatment.
Bro¨mme et al41 reported a reduction of costs per person over
the 12 months following treatment but found that this was not
maintained beyond 12 months, they suggested that this was
because people gradually returned to their preintervention
habits. In contrast, Busch et al42 demonstrated an overall cost
reduction of €3583 per subject 12 months after MBR42; taking
into account the costs of the intervention, disability pension,
and incremental costs of sick leave they projected the interven-
tion would result in a reduction of €53 382 per subject over 10
years (Table 5).42
Work Ability. Sick leave and return to work (RTW) were the 2
main indicators of work ability (Table 6). Sick leave is
defined as absence from work due to illness, whereas RTW
relates to the number of workers who returned to work after a
defined period of sick leave. Three out of 5 studies reported a
moderate to strong P value with regard to RTW in the 12
months after MBR (P < .01 to P < .001). Of the remaining
2 studies, one did not report work-related follow-up data44
and the other mentioned RTW only in passing.54 The 1-year
follow-up data on sick leave present a similar picture. All 3
studies demonstrated moderate to large ESs in sick-leave
duration over time, however, some conflicting results must
be mentioned. Roche-Leboucher et al,51 who compared MBR
with active physical therapy (PT), found a highly significant
reduction in sick leave days over a 12-month MBR follow-up
but over the same period there was no group difference in
RTW.
Over longer follow-up periods. the results are mixed.
Busch et al42 demonstrated a clear long-term improvement
in sickness absence, reporting that the treatment group man-
aged on average 436 more workdays than the control group
over a 10-year period, whereas Bro¨mme et al41 found that the
marked increase in costs relative to a control group over the
first 12 months after MBR (€ 2969.3; 95% CI 3273.1 to
2665.6) was not maintained41: The costs of both groups
were similar for the period between 12 and 18 months post-
MBR.41 Finally, Rantonen et al50 found no changes in LBP-
related sick leave days over the 4 years following MBR in
their group of non-sick-listed employees although they did
find that compared with self-treatment guided by a back book,
MBR reduced total sick leave days in the first (odds ratio ¼
0.34, 95% CI 0.14 to 0.81) and second (odds ratio¼ 0.41, 95%
CI 0.19 to 0.88) years after the intervention. They also found
that the MBR group had fewer sick leave periods than the self-
treatment group in the third and fourth years and fewer days of
sick leave in the fourth year.50 We conclude that overall there




This systematic review aimed to examine the literature on the
efficacy, clinical utility, and cost-effectiveness of MBRs (>25
hours per week) including CBT approach, as treatments for per-
sistent LBP or persistent NSLBP. Application of our exclusion
and inclusion criteria resulted in the selection of 13 studies pub-
lished between January 2010 and July 2017. In these studies pain,
disability, HRQoL, and sick leave/RTW were used as indicators
of effectiveness, clinical utility, and monthly costs and QALYs as
measures of cost effectiveness. As expected,19 all studies reported
moderate to large reductions in short- and long-term pain and
disability and, although the results were arguably less impressive,
improvement in HRQoL. It seems reasonable therefore, to con-
clude that MBR has proven short- and long-term efficacy. A high-
quality study demonstrated an impressive projected decrease in
direct and indirect costs of €53 382 per subject over 10 years.42
The other 2 studies that looked at cost-effectiveness also con-
firmed that over 12 months MBR was cost-effective.41,46 Unfor-
tunately, Henchoz et al46 were not able to calculate incremental
cost-effectiveness ratios of the increase in QALYs following
MBR due to methodological shortcomings. In summary, the lit-
erature presented in this review generally suggests that MBR is
both clinically effective and cost-effective for patients with per-
sistent LBP or persistent NSLBP. Furthermore, the studies
included in the review demonstrate that the feasibility and utility
of MBR extends to a variety of settings.12
Eleven of the 13 studies identified in the systematic litera-
ture search reported the work ability of patients treated by
MBR. All found moderate to large effects on RTW and dura-
tion of sick leave that persisted for at least 12 months. There
were, however, some conflicting results. Bro¨mme et al51 found
that after more than 12 months MBR had no effect on sick
leave. Taking into consideration the methodological quality
of the selected studies we are unable to draw a conclusion about
the long-term impact of MBR, although they hint at a tendency
toward a long-lasting impact on work ability. This is crucial as
work ability is a more sensitive indicator of work-related pro-
ductivity losses than absenteeism or duration of sick leave.
Norlund et al,62 Hoefsmit et al,63 and Øyeflaten et al64 all
reported that treatments similar to MBR had a positive impact
on RTW and through this, reduced the long-term indirect
costs.41 However, evidence remains conflicting.19,65-67 Further
high-quality investigations are needed.
Strengths and Limitations
This systematic review has several strengths, including meth-
odological rigor as it complies with the PRISMA guide-
lines35,36 and uses the GRADE approach to indicate the
quality of the evidence reviewed.37 We also used well-
defined inclusion criteria and selected only original articles
involving a clearly-defined MBR intervention including a CBT
element19 with a follow-up period of at least 12 months.
Finally, our review examines studies using outcome measures










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































relevant to the efficacy, clinical utility, and cost-effectiveness
of MBR in people with persistent LBP or persistent NSLBP.29
The main limitations include the low number of studies
included and the lack of high-quality studies. Well-defined
inclusion criteria clearly limit the number of eligible studies.
Our sample of 13 studies represents 1.1% of the 1199 publica-
tions originally identified and is higher than the 0.7% inclusion
rate Kamper et al19 reported in their Cochrane review. The sec-
ond main limitation of our review is the lack of high-quality
studies. There is a need for high-quality studies of MBR, partic-
ularly with regard to its impact on work ability and sick leave.
In this review, we addressed the lack of high-quality studies
by examining indicators of the economic success of MBR. The
lack of standardization of outcome domains is one of the most
urgent problems affecting reporting of MBR outcomes in cases
of persistent pain.68 In an attempt to offer a fresh perspective
Wieser et al69 reported the economic consequences of LBP or
NSLBP from a societal perspective, distinguishing between 2
productivity losses: work absenteeism, a temporary absence
from work due to LBP or NSLBP, and work presenteeism, the
reduced productivity of employees working despite illness. Not
surprisingly, presenteeism added much more to the costs than
absenteeism.69 It remains unclear, however, to which group
patients returning to work after a period of sick leave should
be assigned. Given the burgeoning personal and public costs of
LBP further high-quality analyses of the temporal pattern of
productivity losses are warranted.9 Surprisingly, our selection
criteria resulted in an exclusively European sample, which may
limit the generalizability of the results to other regions; we
speculate that our search terms and defined inclusion and
exclusion criteria may be biased by our European perspective
despite our international experience. However, with regard to
Kamper et al,19 who did not detect substantially different
effects in treatments with a high intensity (>25 hours per week)
compared with less intensive interventions, one could presume
that less intensive interventions are to be favored. Furthermore,
performing an intensive intervention with at least 25 hours of
treatment per week might substantially reduce its clinical util-
ity with regard to time needed and efficiency of the treatment.
Further methodological limitations include the lack any mea-
sure of the heterogeneity (Q or I2) of outcome measures,
although as this is a systematic review rather than a meta-
analysis heterogeneity testing would not generally be expected.
Implications
The results presented here confirm that MBR is effective as a
treatment for persistent LBP and persistent NSLBP, and that
there is a tendency for MBR to be cost-effective in such cases,
at least over the first 12 months after treatment. In summary,
the evidence suggests that these multidisciplinary treatments
have therapeutic benefits, but the next aim of international
experts and experienced clinicians should be to agree on a core
set of outcome variables. With regard to sick leave or RTW
issues, different study approaches are needed, addressing dis-
abling work characteristics or maladaptive beliefs, emotions
and fears. For example, a recent study presented the Yellow
Flag Questionnaire (YFQ),70 a mixture of established yellow
flag questions developed via a Delphi process.70 Moreover, a
recent systematic review underlined the effectiveness of psy-
chologically informed physical therapy (PIPT) for patients with
persistent LBP with regard to the outcomes pain, pain interfer-
ence, disability, and pain self-efficacy. Further high-quality
investigations, however, are needed to gain knowledge about
the cost-effectiveness of PIPT.71
Conclusion
Multidimensional treatments for patients with persistent LBP
or persistent NSLBP are effective although there is room for
improvement in cost-effectiveness and impact on sickness
absence. A degree of tailoring of treatment to individual needs
might improve the cost-effectiveness of such treatments or
their impact on RTW.
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